| 0.478 0.088 (22.63%) | 02-07 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Sio Gene Therapies Inc. is a biotechnology company in the clinical development phase, committed to pioneering gene therapies designed to fundamentally alter the prognosis for patients afflicted with neurodegenerative conditions. Its therapeutic pipeline is supported by strategic licensing agreements, including one with Oxford BioMedica (UK) Ltd. for the advancement and market introduction of AXO-Lenti-PD and associated gene therapy offerings. Furthermore, Sio Gene Therapies collaborates with The University of Massachusetts Medical School on the development and commercialization of other gene therapy candidates, notably AXO-AAV-GM1 and AXO-AAV-GM. Incorporated in 2014 and headquartered in New York, New York, the entity was known as Axovant Gene Therapies Ltd. prior to its renaming in November 2020.
Fri, 02 Feb 2024
Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share - Yahoo Finance
Mon, 31 Jul 2023
SIO GENE THERAPIES: SIOX Stock Price Quote & News - Robinhood
Sat, 22 Jul 2023
Axovant Gene Therapies: AXGT Stock Price Quote & News - Robinhood
Fri, 28 Apr 2023
Alluvial Capital Management Q1 2023 Letter To Partners - Seeking Alpha
Mon, 28 Nov 2022
Dan Oren Net Worth (2026) - GuruFocus
Sat, 05 Nov 2022
Michael Adasczik Net Worth (2026) - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|